1. Baranov, A.E. and Rozhdestvensky, L.M., Analytical review of treatment regimens for acute radiation sickness used in experiments and in clinical practice, Radiats. Biol. Radioekol., 2008, vol. 48, no. 3, pp. 287–302.
2. Gershanovich, M.L. and Filatova, L.V., Betaleikin (rekombinantnyi interleykin-1β) – effektivnyi stimulyator i protektor leikopoeza v usloviyakh kombinirovannoi khimioterapii zlokachestvennykh opukholei: posobiye dlya vrachei (Betaleukin (Recombinant Interleukin-1β) Is an Effective Stimulant and Protector of Leukopoiesis in Conditions of Combined Chemotherapy of Malignant Tumors: A Guide for Physicians), St. Petersburg: Novaya Al’ternativnaya Poligrafiya, 2008, pp. 1–16.
3. Rozhdestvensky, L.M., Medical support of radiation incidents: urgent organizational, scientific, and regulatory issues, Med. Ekstrem. Situats., 2017, no. 2 (60), pp. 143–148.
4. Singh, V.K., Seed, T.M., et al., A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: parts I, II, III, Int. J. Radiat. Biol., 2017, vol. 93, no. 9, pp. 851–906.
5. Yuhas, J.M., A more general role for WR_2721 in cancer therapy, Br. J. Cancer, 1980, vol. 41, no. 5, pp. 832–834.